Artrya raises $15 million

ASX-listed Artrya, which is commercialising coronary disease diagnosis support products, has announced a successful $15 million raise through a share placement.

In a statement on Friday, the company said it had received binding commitments under a two-tranche placement at $0.73 per share. 

The proceeds will be used to progress regulatory applications for its Salix Coronary Plaque (SCP) &  Salix Coronary Flow (SCF) products, as well as “customer implementation, clinical studies, research & development, regulatory costs” as well as working capital and commencing a flagship plaque study.

Artrya’s Salix is described as a coronary computed tomography angiography (CCTA) image analysis solution that uses artificial intelligence, and which is able to “accurately [assess] and [detect] plaque features, in real-time, without the need for invasive interventions”. 

CEO Mathew Regan said in a statement: “The team is delighted to be raising capital at such an important inflection point in the Company’s history.  

“Clearance from the US Food and Drug Administration (FDA) in relation to regulatory approval for the Salix Coronary Anatomy product is expected in March 2025.” 

Earlier this week the company announced a multi-year commercial contract with Sonic Healthcare, which has over 125 radiology centres across Australia.

Artrya was a Top 10 Gold Award winner in this title’s Australia’s 50 Most Innovative Manufacturers campaign last year.

Picture: credit Artrya

Further reading

Australia’s 50 Most Innovative Manufacturers for 2024 announced

Manufacturing news briefs – stories you might have missed